Skip to content

Study · Not a test of the peptide alone · 2026

2 results

Weight Loss, Obesity Medication, and Risk of Obesity-Associated Cancer: A Meta-Analysis of Randomized Controlled Trials.

Li C, Lin C, Cai X, Lv F, Yang W, Ji L

Obesity (Silver Spring, Md.)4 Nov 2025Cited by 3 (Europe PMC)

PMID41189318 (opens in a new tab)PMCIDPMC13535721 (opens in a new tab)DOI10.1002/oby.70054 (opens in a new tab)PepBankPUB-41189318
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Tirzepatide.

  1. 01HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome

    In patients with overweight or obesity, pooled coagonists (tirzepatide, cotadutide and cagrilintide) reduced overall obesity-associated cancer risk (RR 0.43).

    In plain wordsIn people with overweight or obesity, a group of dual-action drugs including tirzepatide was linked to a lower overall obesity-related cancer risk.

    Peptide
    Tirzepatide
    Outcome
    DecreaseOverall obesity-associated cancer risk, coagonist subgroup
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer

    Measurements

    RR
    0.43 ratio
    coagonists, overall obesity-associated cancer

    Source sentences

    Summary
    coagonists (tirzepatide, cotadutide, and cagrilintide) significantly reduced overall obesity-associated cancer risk (RR = 0.43, 95% CI: 0.19 to 0.97)
    2 context sentences
    Summary · context
    PubMed, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, and the ClinicalTrials.gov website were systematically searched for randomized controlled trials of AOMs from inception to December 2024.
    Summary · context
    The analysis included 25 randomized controlled trials with 40,731 participants.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  2. 02HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome

    In patients with overweight or obesity, every 5 kg weight reduction mediated by pooled coagonists (including tirzepatide) was marginally associated with lower overall obesity-associated cancer risk (RR 0.79).

    In plain wordsIn people with overweight or obesity, each 5 kg of weight lost with this drug group was linked to a slightly lower cancer risk.

    Peptide
    Tirzepatide
    Outcome
    DecreaseObesity-associated cancer risk per 5 kg weight reduction, coagonist subgroup
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer

    Measurements

    RR
    0.79 ratio
    coagonists, per 5 kg weight reduction

    Source sentences

    Summary
    every 5 kg weight reduction mediated by coagonists was marginally associated with a reduced overall obesity-associated cancer risk (RR = 0.79, 95% CI: 0.62 to 1.00).
    2 context sentences
    Summary · context
    PubMed, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, and the ClinicalTrials.gov website were systematically searched for randomized controlled trials of AOMs from inception to December 2024.
    Summary · context
    The analysis included 25 randomized controlled trials with 40,731 participants.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 3 to 38Current

    28 Oct 2026, 02:04 UTC

    The same notice was added 36 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.